BIO-key International Enters Warrant Inducement Transaction
BIO-key International, Inc. (NASDAQ: BKYI) based in Holmdel, N.J., has announced a strategic warrant inducement agreement with an existing institutional investor. This agreement involves the exercise of particular outstanding warrants that were initially issued on a previous date, signifying a robust move in the biometric authentication sector.
Details of the Warrant Inducement Agreement
The investor has agreed to exercise the current Series A and Series B Warrants, paving the way for the purchase of a substantial 3,091,668 shares of the Company's common stock. This transaction is set at a reduced exercise price of $1.02 per share, with gross proceeds estimating to be approximately $3.1 million, before placement agent fees and other expenses. This infusion of funds strengthens BIO-key's financial footing as it continues to expand its biometric solutions.
Role of Placement Agents in the Transaction
Acting as the exclusive Placement Agent for this transaction is Maxim Group LLC, which plays a crucial role in facilitating financial agreements and investment opportunities for BIO-key. Their expertise in capital markets helps ensure successful outcomes in such large financial transactions.
New Warrants Issued to Investors
As part of the agreement, the company has also committed to issuing unregistered New Warrants to the investor. These new warrants will enable the purchase of an additional 6,183,336 shares of common stock at the same exercise price of $1.02 per share. This not only gives the investor a foothold in the company's future gains but also fortifies BIO-key's market presence immediately upon issuance.
Implications of the New Warrants
The New Warrants are set to be immediately exercisable and will expire five years from their date of issuance. Moreover, the company is poised to file a registration statement with the Securities and Exchange Commission (SEC), which will facilitate the resale of shares that can be issued upon the exercise of these New Warrants. This move is aligned with BIO-key’s ongoing commitment to transparency in its operations.
The Vision and Growth of BIO-key International
BIO-key International is truly at the forefront of innovation in cybersecurity with its multi-factor authentication solutions that utilize biometrics. With a user base surpassing forty million, the company is dedicated to assisting businesses in selecting ideal authentication methods, ranging from phoneless to passwordless options. Their flagship product, PortalGuard, stands out for its adaptability, whether deployed in the cloud or on-premise, providing secure and efficient access to sensitive data and operations.
Future Outlook for BIO-key
As the security landscape continues to evolve, BIO-key International is positioned to lead with its differentiated solutions. The firm's knack for fusing technology and user needs into practical identity and access management systems sets the stage for long-term growth. The recent warrant transaction is an excellent illustration of the company's capability to leverage its offerings for financial gain while still focusing on delivering high-quality services to its customers.
Frequently Asked Questions
What is the purpose of the warrant inducement agreement?
The warrant inducement agreement allows BIO-key to raise approximately $3.1 million through the exercise of outstanding warrants by an institutional investor.
What will BIO-key do with the proceeds from this transaction?
The funds will help strengthen BIO-key's position in the biometric authentication market, enabling further innovation and expansion of their solutions.
What are New Warrants in this context?
New Warrants are unregistered warrants that allow the investor to purchase additional shares of BIO-key's common stock at an exercise price of $1.02.
How does this transaction affect existing shareholders?
The exercise of these warrants could potentially dilute existing shares, but it also provides necessary funds that may enhance the company's growth and market position, benefiting shareholders in the long run.
Who should investors contact for more information?
Investors can reach out to William Jones or David Collins at Catalyst IR for further details regarding this announcement.
